Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

Zhang, BS; Gorman, J; Kwon, YD; Pegu, A; Chao, CW; Liu, T; Asokan, M; Bender, MF; Bylund, T; Damron, L; Gollapudi, D; Lei, PL; Li, YL; Liu, CP; Louder, MK; McKee, K; Olia, AS; Rawi, R; Schön, A; Wang, SS; Yang, ES; Yang, YP; Carlton, K; Doria-Rose, NA; Shapiro, L; Seaman, MS; Mascola, JR; Kwong, PD

Kwong, PD (通讯作者),NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.

MABS, 2023; 15 (1):

Abstract

Antibody CAP256-VRC26.25 targets the second hypervariable region (V2) at the apex of the HIV envelope (Env) trimer with extraordinary neutralization p......

Full Text Link